Atai Life Sciences Valued At More Than $3 Billion After IPO
German psychedelic pharmaceutical company Atai Life Sciences is valued at more than $3 billion after its IPO listing on the Nasdaq.
Day: June 19, 2021
27 Publicly-Traded Psychedelic Stocks Investors Have Their Eyes On
These psychedelic stocks are all publicly trading. Take a look at the companies leading the psychedelic medicine revolution.
End of content
End of content